American Bio Medica Corp

Fatalities tied to synthetic opioids and illegal fentanyl climbed 38.4 percent in the 12 months ending in May 2020, compared with the same period ending in May 2019, according to the CDC. The spike in overdose deaths tied to these substances was even steeper in several parts of the country, almost doubling in 10 Western states. If you know someone struggling with addiction during the pandemic, you should check in with them regularly and offer to help them access treatment. Contact ABMC at 800-227-1243 or via email at [email protected] to discuss your testing options for drugs or Covid-19.

FOR IMMEDIATE RELEASE: ABMC DISTRIBUTES RAPID ANTIGEN TEST FOR COVID-19 Kinderhook, N.Y., December 14, 2020 American Bio Medica Corporation (OTCQB: ABMC), a m...anufacturer of accurate, cost-effective immunoassay test kits, announced today that it is now distributing a Rapid Covid-19 Antigen test. The Rapid Antigen test is an immunochromatographic assay for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal (NP) swab from individuals who are suspected of COVID-19 by their healthcare provider. It is intended to aid in the rapid diagnosis of SARS-CoV-2 infections. The test can currently only be used by laboratories in the United States certified to perform high complexity testing, including testing at point-of-care when the site is covered by the laboratory’s CLIA certificate of high complexity. The test is CE-marked and can be sold to locations outside the United States. The Rapid Antigen test is not for home use or at-home specimen collection. The test provides results in 15 minutes. Chief Executive Officer Melissa A. Waterhouse stated, The Rapid Antibody test is yet another great complement to our Covid-19 testing portfolio. Our goal is to be able to provide our customers with as many testing options as possible so they can effectively manage their testing programs and get this virus under control. To place an order, customers can call (800) 227-2343, or (518) 758-8158 outside the United States or, contact the company via email at [email protected]. For more information on ABMC or its testing products, please visit www.abmc.com. About American Bio Medica Corporation American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse, and distributes a rapid test to detect Covid-19 antibodies, a RT-PCR test to detect Covid-19 and a rapid Covid-19 antigen test. The Company also currently manufactures (on a contract basis) tests to detect respiratory syncytial virus (RSV) and malaria and, with the ability to manufacture tests for many other medical conditions, viruses and diseases in its FDA registered and ISO certified facilities. This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, future sales and profit levels of the rapid antibody test and RT-PCR test for Covid-19 that we are distributing, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to penny stock rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled Risk Factors in the Company's annual report on Form 10-K for the year ended December 31, 2019, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares. ##### See more

Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 ...Continue reading

Our Kinderhook office will be closed today (October 8, 2020) due to a power outage. We expect to reopen at 8am tomorrow. We apologize for any inconvenience this may cause our customers or vendors.

ABMC REPORTS SECOND QUARTER 2020 RESULTS Kinderhook, N.Y., September 15, 2020 American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and six months ended June 30, 2020. Chief Executive Officer Melissa A. Waterhouse stated, We are pleased to report increased sales when comparing 2020 to 2019 (from both a quarter over quarter and year over year perspective) as a result of our distribution of the Covid-19 antibody test. There are a numb...er of sales opportunities for the Covid-19 test in the pipeline and marketing applications yet to come for the product. In the meantime, it has been well received by customers. From an operational perspective, selling and marketing expense increased (due to commissions paid on sales of the rapid Covid-19 test), however, all other expenses decreased in the second quarter of 2020 even with increased sales. This allowed us to achieve operating income in the second quarter of 2020. Waterhouse continued, As the market for Covid-19 testing is developing, we are reviewing alternative products to offer our customers in addition to the antibody tests and looking for avenues to capitalize on our manufacturing operations. As indicated in our last announcement, we are seeing some rebound in the drug testing markets as businesses and treatment programs re-open, but we are still uncertain if or how long this rebound will continue as the pandemic progresses. Financial Highlights Net sales in the second quarter of 2020 were $1,758,000, compared to net sales of $958,000 in the second quarter of 2019; an increase of $800,000, or 83.5%. Net sales in the six months ended June 30, 2020 were $2,486,000, compared to $1,880,000 in the six months ended June 30, 2019; an increase of $606,000, or 32.2%. Operating income was $16,000 in the second quarter of 2020, compared to an operating loss of $155,000 in the second quarter of 2019. Operating loss was $255,000 in the six months ended June 30, 2020, compared to an operating loss of $329,000 in the six months ended June 30, 2019. Net loss was $21,000, or $(0.00) per share in the second quarter of 2020, compared to net loss of $56,000, or $(0.00) per share, in the second quarter of 2019. Net loss was $346,000, or $(0.01) per share, in the six months ended June 30, 2020, compared to net loss of $296,000, or $(0.01) per share, for the six months ended June 30, 2019. For more information on ABMC or its drug testing products, please visit www.abmc.com. See more

We may be celebrating differently this year but, we can still enjoy the weekend and make new memories. Stay safe and well!

On March 20, 2020, ABMC announced in a press release that it was offering a COVID-19 Antibody Rapid Detection Kit to detect COVID-19 in whole blood, serum or plasma via finger stick. On May 29, 2020, the COVID-19 test being distributed by ABMC was authorized by the United States Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for use by authorized laboratories. The product, manufactured by Healgen Scientific, LLC, has been authorized only for the... presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. The product is intended for professional use and not for home use. ABMC will continue to market the COVID-19 test in full compliance with FDA policy and the EUA. If you would like to know more or see if you qualify to purchase, call 800-227-1243 or email [email protected] and one of our representatives will be happy to assist you.

What a week it has been! It seems COVID-19 testing options are becoming more and more suspect. Does the test work? Who is the company you are trying to do business with? Are they who they say they are? Here’s our advice.... Do your homework on both the test and the Company. Is the technology sound? Is the Company registered with any government agencies? Do they have medical device clearances and are they subject to FDA audits. The answers to the homework questions are ALL yes if American Bio Medica is the Company you are considering! Give us a call 800-227-1243 or email us at [email protected]. Stay safe and be kind to one another in this difficult time.

NOW AVAILABLE FOR SALE GLOBALLY! COVID-19 Rapid Test COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid phase immunochromatographic assay for the rapid, qualitative and differential detection of IgG and IgM antibodies to 2019 Novel Coronavirus in human whole blood, serum or plasma. 25 tests per box... Call or email for pricing; volume pricing available Within the US: 800-227-1243 Outside the US: 518-758-8158 Email: [email protected] Disclaimer: The COVID-10 Rapid Test has not yet been reviewed by the US Food and Drug Administration; however, a EUA authorization will be filed within 15 days of marketing as required under current FDA guidance. The COVID-19 test should not be used as the sole basis to diagnose or exclude infection or to inform infection status.